These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants. Ehrmann E; Jolivet-Gougeon A; Bonnaure-Mallet M; Fosse T J Antimicrob Chemother; 2017 Aug; 72(8):2208-2212. PubMed ID: 28453633 [TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of 96 Capnocytophaga strains, including a beta-lactamase producer, to new beta-lactam antibiotics and six quinolones. Arlet G; Sanson-Le Pors MJ; Casin IM; Ortenberg M; Perol Y Antimicrob Agents Chemother; 1987 Aug; 31(8):1283-4. PubMed ID: 3498438 [TBL] [Abstract][Full Text] [Related]
8. A series of infections due to Capnocytophaga spp in immunosuppressed and immunocompetent patients. Bonatti H; Rossboth DW; Nachbaur D; Fille M; Aspöck C; Hend I; Hourmont K; White L; Malnick H; Allerberger FJ Clin Microbiol Infect; 2003 May; 9(5):380-7. PubMed ID: 12848750 [TBL] [Abstract][Full Text] [Related]
9. [The prevalence and antibiotic susceptibility of Capnocytophaga and Actinobacillus actinomycetemcomitans in the periodontal pockets of periodontitis patients with insulin-independent diabetes mellitus]. Son SH; Choi SM; Han SB; Chung CP Taehan Chikkwa Uisa Hyophoe Chi; 1986 Nov; 24(11):961-8. PubMed ID: 3474309 [No Abstract] [Full Text] [Related]
10. In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents. Rummens JL; Gordts B; Van Landuyt HW Antimicrob Agents Chemother; 1986 Nov; 30(5):739-42. PubMed ID: 3800350 [TBL] [Abstract][Full Text] [Related]
11. Capnocytophaga spp. involvement in bone infections: a review. Piau C; Arvieux C; Bonnaure-Mallet M; Jolivet-Gougeon A Int J Antimicrob Agents; 2013 Jun; 41(6):509-15. PubMed ID: 23642766 [TBL] [Abstract][Full Text] [Related]
13. Selective recovery of oral Capnocytophaga spp. with sheep blood agar containing bacitracin and polymyxin B. Mashimo PA; Yamamoto Y; Nakamura M; Slots J J Clin Microbiol; 1983 Feb; 17(2):187-91. PubMed ID: 6833474 [TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibilities of Capnocytophaga isolates to beta-lactam antibiotics and beta-lactamase inhibitors. Jolivet-Gougeon A; Buffet A; Dupuy C; Sixou JL; Bonnaure-Mallet M; David S; Cormier M Antimicrob Agents Chemother; 2000 Nov; 44(11):3186-8. PubMed ID: 11036049 [TBL] [Abstract][Full Text] [Related]
15. [Bacteremia due to Capnocytophaga species during chemotherapy-induced neutropenia in patients with hematological malignancies]. Murakami K; Mori T; Kato J; Shimizu T; Kohashi S; Sakurai M; Sugita K; Hasegawa N; Murata M; Okamoto S Rinsho Ketsueki; 2017; 58(3):210-215. PubMed ID: 28381687 [TBL] [Abstract][Full Text] [Related]
16. Bactericidal activities of synthetic human leukocyte cathepsin G-derived antibiotic peptides and congeners against Actinobacillus actinomycetemcomitans and Capnocytophaga sputigena. Miyasaki KT; Bodeau AL; Pohl J; Shafer WM Antimicrob Agents Chemother; 1993 Dec; 37(12):2710-5. PubMed ID: 8109940 [TBL] [Abstract][Full Text] [Related]